Acelrx pharmaceuticals announces publication of clinical data on the use of sufentanil sublingual tablet during awake plastic surgery procedures

Hayward, calif., feb. 1, 2022 /prnewswire/ -- acelrx pharmaceuticals, inc. (nasdaq: acrx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced the publication of real-world data in patients undergoing awake plastic surgery showing a rapid recovery time and minimal side effects with the use of sufentanil sublingual tablet (sst) for pain management.
ACRX Ratings Summary
ACRX Quant Ranking